title: Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.
abstract: Systemic lupus erythematosus (SLE) patients may have psychiatric manifestations during the illness course. Psychotropic agents are indicated in treating these symptoms. Second-generation antipsychotics, such as risperidone, olanzapine and quetiapine, have been thought to be safer than clozapine with regard to the side effect of neutropenia or agranulocytosis. We report a case of SLE who developed agranulocytosis during the treatment with olanzapine for the SLE-related psychiatric symptoms.
authors.affiliation: Department of Psychiatry, Chang Gung Memorial Hospital, Chia Yi Shen 61344, Taiwan, R.O.C.
authors.forename: Jian-An
authors.initials: JA
authors.lastname: Su
authors.forename: Chien-Hui
authors.initials: CH
authors.lastname: Wu
authors.forename: Hin-Yeung
authors.initials: HY
authors.lastname: Tsang
mesh_terms: D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000150:complications*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000523:psychology*; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine